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Methods: A total of 55 patients with rosacea and 37 control subjects participated in the study. Corneal and conjunctival sensitivity
was determined by Cochet-Bonnet esthesiometer. Subjective symptoms of ocular dryness were evaluated using Ocular Surface
Disease Index (OSDI). Schirmer’s I test (ST), tear breakup time (tBUT) and ocular surface staining with fluorescein were carried
out to measure objective signs.
Results: The mean corneal and conjunctival sensitivity did not differ significantly between rosacea patients and controls (all
p > 0.05). Schirmer’s I test and tBUT were significantly reduced (p = 0.004 for OD and p < 0.001 for OS) and grade of ocular
surface staining was significantly high (p = 0.018 for OD and p = 0.038 for OS) in rosacea patients. Corneal and conjunctival
sensitivity did not show significant correlation with ST, tBUT, ocular surface staining (Oxford Schema), duration of rosacea and
OSDI score.
Conclusions: Corneal and conjunctival sensitivity did not change significantly in rosacea.
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Rosacea is a common chronic disease with unknown
pathogenesis. It is characterized by inflammation and
vascular abnormalities of the central facial skin.1 Previous
studies demonstrated upregulation of genes involved in
vasoregulation and neurogenic inflammation and suggested
that dysregulation of mediators and receptors implicated in
neurovascular and neuroimmune communication may be
important at early stages of the disease.2–4
Although considered as a skin disease, rosacea may affect
eye in up to 58–72% of the patients. Superficial punctate
keratitis, peripheral neovascularization associated with
subepithelial marginal infiltrates, stromal ulceration,
corneal perforation, recurrent corneal epithelial erosions,pseudodendritic ulcer, pseudokeratoconus, and infectious
keratitis have been previously reported. Conjunctival
manifestations are chronic conjunctivitis, chronic papillary
reaction, cicatricial conjunctivitis, pinguecula, conjunctival
fibrosis and symblepharon. Blepharitis and meibomian gland
dysfunction are also common findings. Dry eye with abnormal
Schirmer’s I test (ST) and shorter tear breakup time (tBUT) has
also been reported in a majority of patients with ocular
rosacea.5–9
Up to now, no studies have been conducted to see the
effects of rosacea on corneal and conjunctival sensitivity. In
this study, in order to contribute in the clarification of the
involvement of tear function in rosacea, we evaluated both
the incidence of subjective symptoms and objective signs
of dry eye and measured corneal and conjunctival sensitivitye:
al.com
30 N. Örnek et al.in rosacea patients. We also assessed the relationship among
the symptoms and signs of dry eye and corneal and conjunc-
tival sensitivity in these patients.Table 2. Corneal and conjunctival sensitivity of rosacea patients and
controls.
Rosacea
group
(n = 55)
Control
group
(n = 37)
p
value*
Corneal sensitivity (mm) OD 56.9 ± 7.7 58.7 ± 2.8 0.1
OS 57.2 ± 6.1 58.8 ± 2.7 0.1
Temporal conjunctival
sensitivity (mm)
OD 12.7 ± 6.3 11.2 ± 4.9 0.2
OS 12.6 ± 6.4 11.1 ± 4.9 0.2
Nasal conjunctival
sensitivity (mm)
OD 11.6 ± 6.3 9.2 ± 4.0 0.039
OS 12.0 ± 6.6 10.5 ± 4.7 0.2
* p=<0.05.
Table 1. Characteristics of rosacea patients and controls.
Rosacea group
(n = 55)
Control group
(n = 37)
p
value*
Age (years) 47.2 ± 11.9 48.7 ± 12.6 0.5
OSDI (0–100) 20.18 ± 15.4 16.4 ± 11.9 0.2
Ocular surface
staining
OD 1.67 ± 1.9 0.86 ± 1.0 0.018
OS 1.51 ± 1.7 0.86 ± 0.9 0.038
Schirmer’s I test
(mm)
OD 12.56 ± 4.4 15.57 ± 5.5 0.004
OS 12.18 ± 5.1 17.05 ± 5.5 <0.001
tBUT (seconds) OD 7.16 ± 2.7 10.19 ± 2.9 <0.001
OS 8.15 ± 3.1 10.59 ± 3.0 <0.001
*p=<0.05.Materials and methods
Fifty-five patients (43 women and 12 men) diagnosed as
rosacea at the Department of Dermatology by an expert der-
matologist between August 2012 and November 2013 were
enrolled into this prospective study. Thirty-seven healthy sub-
jects (30 women and 7 men) from the Ophthalmology
Department outpatient clinic served as control group. Writ-
ten informed consent was obtained from all the participants.
The study was approved by the Institutional Review Board
and was conducted in accordance with the Declaration of
Helsinki.
Subjects with previous ocular surgery and trauma, mani-
fest anterior segment infection, history of refractive surgery
and contact lens wear, diabetes mellitus, hepatitis and those
using systemic and topical therapeutic agents that may affect
ocular surface sensitivity were excluded from the study.
Each participant underwent a complete ophthalmological
examination including best-corrected visual acuity, measure-
ment of intraocular pressure and slit lamp examination.
Schirmer’s test was done with test strips. The strip was
positioned behind the lower lid between the temporal and
middle thirds, and the patient kept his/her eyes closed for
5 min, after that the strips were removed and the length of
the moistened area was measured.
One drop of 1.25 mg/ml of sodium fluorescein was
instilled in the lower conjunctival sac, and corneal, nasal con-
junctival and temporal conjunctival staining was graded from
0 to 5 according to the Oxford Schema.10 The mean of these
three quadrants was used for statistical analysis. The tear
breakup time was the average duration between the last
complete blink and the first appearance of randomly dis-
tributed dry spot under cobalt blue filtered light.11 Dry eye
was diagnosed if a symptomatic patient had abnormal tBUT
(65 s) and ST (610 mm in 5 min).
All subjects filled out the OSDI report which assessed the
symptoms of ocular irritation consistent with dry eye disease
and their impact on vision-related functioning. OSDI
questionnaire with 12 items was graded on a scale from
0 to 4, where 0 indicated none of the time; 1, some of the
time; 2, half of the time; 3, most of the time; and 4, all of
the time. The total OSDI score was then calculated with the
following formula: OSDI = (sum of scores for all questions
answered)  100/(total number of questions answered)  4.
OSDI is assessed on a scale of 0–100, with higher scores
representing greater disability.12
Corneal and conjunctival sensitivity was measured using
the Cochet-Bonnet esthesiometer which mechanically stimu-
lates the ocular surface with a nylon filament of diameter
0.08 mm. All measurements were done by a single observer
between 9 AM and 4 PM. The tactile sensitivity was assessed
close to the center of the cornea and at temporal and nasal
bulbar conjunctiva, 3–4 mm away from the limbus along the
horizontal meridian as judged by simple inspection. The
patients were asked to redirect their gaze prior to the stimu-
lus cycle. The test was started at the maximal length of
60 mm. If no response was obtained at 60 mm, the length
was reduced by 5 mm until a positive response was obtained.Assessment of the tactile threshold was made by defining the
length of the filament which was detectable by the subject in
two of three randomly repeated trials.
Statistical analysis was done by SPSS statistical software
(SPSS for windows 10.0, Inc., Chicago, USA). All data were
expressed as mean ± standard deviation (±SD). One way
analysis of variance (ANOVA) and Student’s t-test were used
for the analysis. Statistical significance was defined at a level
of 5% (p < 0.05) and correlation was significant at the 0.01
level (2-tailed).
Results
Fifty-five rosacea patients (43 women, 12 men; mean age:
47.2 ± 11.9 years; range, 14–74) and 37 controls (30 women,
7 men; mean age: 48.7 ± 12.6 years; range, 14–74) involved
in this study. There was no statistically significant difference
between the groups in terms of age and sex (p = 0.5,
p = 0.4, respectively). Mean duration of the disease was
7.6 ± 6.1 (maximum 30; minimum 0.5) years.
Dry eye was diagnosed in 50.9% (n = 28) of rosacea
patients according to ST and tBUT results. Grade of ocular
surface staining was significantly higher in rosacea patients
than controls according to Oxford Schema (p = 0.018 for
OD and p = 0.038 for OS). And ST and tBUT tests’ results
were significantly shorter in rosacea patients than controls
(p = 0.004 for OD and p < 0.001 for OS versus p < 0.001 for
OU). OSDI scores were higher in rosacea patients than in con-
trols but this was not statistically significant (20.18 ± 15.4 vs
16.4 ± 11.9, p = 0.2) (Table 1).
Although mean central corneal sensitivity decreased and
conjunctival (temporal and nasal) sensitivity increased in
rosacea patients, the change was not statistically significant
in both eyes, except for nasal conjunctival sensitivity of right
eye (Table 2).
Table 3. Correlation of corneal and conjunctival sensitivity of the right eye with objective tests and subjective symptoms of dry eye and duration of rosacea.
Corneal sensitivity (mm) Temporal conjunctival sensitivity (mm) Nasal conjunctival sensitivity (mm)
Schirmer’s I test (mm) 0.043 (p = 0.7) 0.094 (p = 0.4) 0.107 (p = 0.4)
tBUT (s) 0.156 (p = 2) 0.012 (p = 9) 0.027 (p = 0.8)
Ocular surface staining 0.077 (p = 0.5) 0.112 (p = 0.4) 0.197 (p = 0.1)
OSDI 0.081 (p = 0.5) 0.32 (p = 0.01) 0.231 (p = 0.1)
Rosacea duration (years) 0.052 (p = 0.7) 0.073 (p = 0.5) 0.139 (p = 0.3)
⁄p=<0.05.
Corneal and conjunctival sensitivity in rosacea 31No significant correlation was detected between corneal
and conjunctival sensitivity of the right eye and ST, tBUT,
ocular surface staining (Oxford Schema), rosacea duration
and OSDI score, except for temporal conjunctival sensitivity
and OSDI score (Table 3).
Discussion
Rosacea is a chronic inflammatory skin disease. The
prevalence of ocular involvement in rosacea is probably
higher than assumed but it varies considerably between
ophthalmological and dermatological studies.5,6 The
incidence of dry eye in rosacea is higher than the normal
population (39–62% versus 15–34%).8,9,13,14 Most of the ocu-
lar symptoms and signs in rosacea are related to dry eye which
is closely associated with inflammation and dysfunction of the
meibomian glands. The dysfunction could be secondary to
increased production of free fatty acids due to bacterial
lipases or facial and angular venous dilation.15–17 These
changes cause abnormal lipid composition of the tear film
leading to shorter tBUT and dry eye. Normal corneal sensitiv-
ity is necessary for maintenance of basic tear secretion.18,19
The etiology of dry eye may change, but an underlying
cytokine-/receptor-mediated inflammatory process is com-
mon to all ocular surface diseases.20 Dry eye is frequently
associated with inflammatory changes both in the lacrimal
glands and on the ocular surface.21 Treating this could nor-
malize the ocular surface/lacrimal neural reflex. Anti-
inflammatory drugs have been beneficial in the treatment of
dry eye.22 Schechter et al. have shown that Cyclosporine-A
is more effective than artificial tears for the treatment of
rosacea-associated eyelid and corneal changes.23
In our study, despite high incidence (50.9%) of dry eye,
corneal and conjunctival sensitivity did not reveal any signifi-
cant difference in rosacea patients. As known mechanical
sensitivity of cornea and conjunctiva to tactile stimulus is
reduced in dry eye.24 Alterations in corneal nerve morphol-
ogy and increased number of antigen-presenting cells, impli-
cating the role of inflammation, may be responsible for the
reduction.25 On the other hand, we know that rosacea
patients are susceptible to certain stimuli.26 The modification
of cutaneous sensitivity indicates the relevance of the sensory
and/or autonomic nervous system in the pathogenesis of the
disease.4 Schwab et al. have shown increased number of
myelinated nerves which are ultimately involved in pain trans-
mission in rosacea.3 Therefore, basal ocular surface sensitivity
may be increased in rosacea patients, but coexisting dry eye
reduces ocular surface sensitivity and brings it to normal
levels.
While grade of ocular surface staining was significantly
higher, subjective symptoms measured by OSDI were only
slightly higher in rosacea patients. Patients with dry eye oftenpresent with ocular surface epithelial disease and complain of
irritation symptoms, but weak correlation in our study sug-
gests that factors other than ocular surface staining may play
a role in OSDI scores.27 Pult et al. also reported weak corre-
lation between dry eye symptoms and objective tests and
corneal staining.28 Ünlü et al. showed absence of correlation
between OSDI and ST scores and blamed reflex tearing that
developed during ST.29 Our results are in accordance with
their findings. Thus, we may conclude that subjective symp-
toms may not correlate with the objective test results of dry
eye in rosacea.
We did not find any significant correlation between
corneal/conjunctival sensitivity and ST, tBUT, ocular surface
staining, rosacea duration and OSDI score (except for tempo-
ral conjunctival sensitivity and OSDI score). Change in ocular
surface sensitivity may be caused by rosacea itself. Although
the pathophysiology of the disease is still poorly understood,
dysfunction of neurovascular regulation and the innate
immune system seems to be the driving forces.30 Normal
ocular sensitivity and a high rate of dry eye in our patients
may be the consequences of neural dysfunction in rosacea.
Corneal and conjunctival sensitivity values may have clini-
cal implications for rosacea patients who may require anterior
segment surgery such as LASIK, keratoplasty, and cataract
surgery. Visual function is an important role of tear film.
Abnormalities in tear function tests may negatively impact
visual quality leading to blurred vision and may also predis-
pose to corneal erosions or other associated complications
in rosacea patients.
There are some limitations to this study. First, we did not
evaluate subtypes of rosacea. Second, we did not measure
the amount of proinflammatory cytokine secretion which
could help to understand the effect of inflammation on cor-
neal sensitivity and fluorescein staining, as correlation
between corneal fluorescein staining and focal inflammation
has been demonstrated in Sjögren syndrome.31,32 Finally,
Cochet-Bonnet esthesiometer measures only mechanical
sensitivity and has limitations in reproducibility and sensitiv-
ity. Changes in the tear film might have affected the intensity
of the mechanical stimulus.
To conclude, the dry eye experienced in rosacea was
found to be not associated with changes in the sensitivity
of ocular surface that was measured with Cochet-Bonnet
esthesiometer. The findings of current study constitute only
preliminary data on ocular surface sensitivity and rosacea
and further studies would be necessary to better understand
the relationship.Conflicts of Interest
The authors declared that there is no conflict of interest.
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